74 related articles for article (PubMed ID: 12874013)
1. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
[TBL] [Abstract][Full Text] [Related]
2. The effects of alphaGalCer-induced TCRValpha24 Vbeta11(+) natural killer T cells on NK cell cytotoxicity in umbilical cord blood.
Ueda Y; Hagihara M; Gansuvd B; Yu Y; Masui A; Okamoto A; Higuchi A; Tazume K; Kato S; Hotta T
Cancer Immunol Immunother; 2003 Oct; 52(10):625-31. PubMed ID: 12802518
[TBL] [Abstract][Full Text] [Related]
3. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
4. The polarization of immune cells in the tumour environment by TGFbeta.
Flavell RA; Sanjabi S; Wrzesinski SH; Licona-Limón P
Nat Rev Immunol; 2010 Aug; 10(8):554-67. PubMed ID: 20616810
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.
Luzzi S; Giotta Lucifero A; Brambilla I; Magistrali M; Mosconi M; Savasta S; Foiadelli T
Acta Biomed; 2020 Jun; 91(7-S):18-31. PubMed ID: 32608373
[TBL] [Abstract][Full Text] [Related]
6. Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity.
Andrews K; Hamers AAJ; Sun X; Neale G; Verbist K; Tedrick P; Nichols KE; Pereira S; Geraghty DE; Pillai AB
Cytotherapy; 2020 May; 22(5):276-290. PubMed ID: 32238299
[TBL] [Abstract][Full Text] [Related]
7. Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer.
Patel S; Burga RA; Powell AB; Chorvinsky EA; Hoq N; McCormack SE; Van Pelt SN; Hanley PJ; Cruz CRY
Front Oncol; 2019; 9():196. PubMed ID: 31024832
[No Abstract] [Full Text] [Related]
8. Tissue-Specific Roles of NKT Cells in Tumor Immunity.
Terabe M; Berzofsky JA
Front Immunol; 2018; 9():1838. PubMed ID: 30158927
[TBL] [Abstract][Full Text] [Related]
9. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.
Mehla K; Tremayne J; Grunkemeyer JA; O'Connell KA; Steele MM; Caffrey TC; Zhu X; Yu F; Singh PK; Schultes BC; Madiyalakan R; Nicodemus CF; Hollingsworth MA
Cancer Immunol Immunother; 2018 Mar; 67(3):445-457. PubMed ID: 29204701
[TBL] [Abstract][Full Text] [Related]
10. Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.
Lam PY; Nissen MD; Mattarollo SR
Front Immunol; 2017; 8():1355. PubMed ID: 29109728
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.
Keller CW; Freigang S; Lünemann JD
Front Immunol; 2017; 8():570. PubMed ID: 28596767
[TBL] [Abstract][Full Text] [Related]
12. Natural killer T cells: drivers or passengers in preventing human disease?
Berzins SP; Ritchie DS
Nat Rev Immunol; 2014 Sep; 14(9):640-6. PubMed ID: 25103356
[TBL] [Abstract][Full Text] [Related]
13. Natural killer T cells in advanced melanoma patients treated with tremelimumab.
Ibarrondo FJ; Yang OO; Chodon T; Avramis E; Lee Y; Sazegar H; Jalil J; Chmielowski B; Koya RC; Schmid I; Gomez-Navarro J; Jamieson BD; Ribas A; Comin-Anduix B
PLoS One; 2013; 8(10):e76829. PubMed ID: 24167550
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.
Song W; Tai YT; Tian Z; Hideshima T; Chauhan D; Nanjappa P; Exley MA; Anderson KC; Munshi NC
Leukemia; 2011 Jan; 25(1):161-8. PubMed ID: 21102427
[TBL] [Abstract][Full Text] [Related]
15. Type I natural killer T cells: naturally born for fighting.
Tan JQ; Xiao W; Wang L; He YL
Acta Pharmacol Sin; 2010 Sep; 31(9):1123-32. PubMed ID: 20694020
[TBL] [Abstract][Full Text] [Related]
16. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.
Nowak M; Arredouani MS; Tun-Kyi A; Schmidt-Wolf I; Sanda MG; Balk SP; Exley MA
PLoS One; 2010 Jun; 5(6):e11311. PubMed ID: 20593019
[TBL] [Abstract][Full Text] [Related]
17. Human leukemic cells loaded with alpha-galactosylceramide (alpha-GalCer) activate murine NKT cells in situ.
Shimizu K; Hidaka M; Bickham K; Moriwaki M; Fujimoto K; Kawano F; Fujii S
Int J Hematol; 2010 Jul; 92(1):152-60. PubMed ID: 20552304
[TBL] [Abstract][Full Text] [Related]
18. The contrasting roles of NKT cells in tumor immunity.
Berzofsky JA; Terabe M
Curr Mol Med; 2009 Aug; 9(6):667-72. PubMed ID: 19689293
[TBL] [Abstract][Full Text] [Related]
19. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.
Dhodapkar MV
Front Biosci (Landmark Ed); 2009 Jan; 14(3):796-807. PubMed ID: 19273100
[TBL] [Abstract][Full Text] [Related]
20. The role of NKT cells in tumor immunity.
Terabe M; Berzofsky JA
Adv Cancer Res; 2008; 101():277-348. PubMed ID: 19055947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
